Thor Medical ASA - Asset Resilience Ratio

Latest as of December 2024: 29.78%

Thor Medical ASA (TRMED) has an Asset Resilience Ratio of 29.78% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Thor Medical ASA for a breakdown of total debt and financial obligations.

Liquid Assets

Nkr123.39 Million
≈ $12.98 Million USD Cash + Short-term Investments

Total Assets

Nkr414.40 Million
≈ $43.61 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2024)

This chart shows how Thor Medical ASA's Asset Resilience Ratio has changed over time. See what is Thor Medical ASA's book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Thor Medical ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Thor Medical ASA stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Nkr123.39 Million 29.78%
Short-term Investments Nkr0.00 0%
Total Liquid Assets Nkr123.39 Million 29.78%

Asset Resilience Insights

  • Very High Liquidity: Thor Medical ASA maintains exceptional liquid asset reserves at 29.78% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Thor Medical ASA Industry Peers by Asset Resilience Ratio

Compare Thor Medical ASA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Biotechnology 43.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Shanghai Junshi Biosciences Co Ltd
SHG:688180
Biotechnology 4.28%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%
Jade Biosciences, Inc.
NASDAQ:JBIO
Biotechnology 80.21%
Theravance Biopharma Inc
F:0TB
Biotechnology 37.29%

Annual Asset Resilience Ratio for Thor Medical ASA (2020–2024)

The table below shows the annual Asset Resilience Ratio data for Thor Medical ASA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.00% Nkr1.00K
≈ $105.23
Nkr414.40 Million
≈ $43.61 Million
-12.77pp
2023-12-31 12.77% Nkr42.25 Million
≈ $4.45 Million
Nkr330.83 Million
≈ $34.81 Million
-77.26pp
2022-12-31 90.03% Nkr98.72 Million
≈ $10.39 Million
Nkr109.64 Million
≈ $11.54 Million
-3.57pp
2021-12-31 93.61% Nkr277.71 Million
≈ $29.22 Million
Nkr296.67 Million
≈ $31.22 Million
+0.17pp
2020-12-31 93.44% Nkr293.98 Million
≈ $30.93 Million
Nkr314.61 Million
≈ $33.11 Million
--
pp = percentage points

About Thor Medical ASA

OL:TRMED Norway Biotechnology
Market Cap
$168.11 Million
Nkr1.60 Billion NOK
Market Cap Rank
#17341 Global
#143 in Norway
Share Price
Nkr4.51
Change (1 day)
-0.33%
52-Week Range
Nkr2.32 - Nkr5.58
All Time High
Nkr121.16
About

Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was incorporated in 2009 and is headquartered in Oslo, Norway.